175 related articles for article (PubMed ID: 27023764)
1. Evaluation of PolyMPC-Dox Prodrugs in a Human Ovarian Tumor Model.
Wong KE; Mora MC; Skinner M; McRae Page S; Crisi GM; Arenas RB; Schneider SS; Emrick T
Mol Pharm; 2016 May; 13(5):1679-87. PubMed ID: 27023764
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of polyMPC-DOX prodrugs in 4T1 tumor-bearing mice.
McRae Page S; Henchey E; Chen X; Schneider S; Emrick T
Mol Pharm; 2014 May; 11(5):1715-20. PubMed ID: 24750072
[TBL] [Abstract][Full Text] [Related]
3. PolyMPC-doxorubicin prodrugs.
Chen X; Parelkar SS; Henchey E; Schneider S; Emrick T
Bioconjug Chem; 2012 Sep; 23(9):1753-63. PubMed ID: 22881479
[TBL] [Abstract][Full Text] [Related]
4. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
[TBL] [Abstract][Full Text] [Related]
5. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
6. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.
Huang S; Fang R; Xu J; Qiu S; Zhang H; Du J; Cai S
J Drug Target; 2011 Aug; 19(7):487-96. PubMed ID: 21284542
[TBL] [Abstract][Full Text] [Related]
8. Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment.
Jayant S; Khandare JJ; Wang Y; Singh AP; Vorsa N; Minko T
Pharm Res; 2007 Nov; 24(11):2120-30. PubMed ID: 17668297
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
[TBL] [Abstract][Full Text] [Related]
10. Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice.
Zhou L; Cheng R; Tao H; Ma S; Guo W; Meng F; Liu H; Liu Z; Zhong Z
Biomacromolecules; 2011 May; 12(5):1460-7. PubMed ID: 21332185
[TBL] [Abstract][Full Text] [Related]
11. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
12. Polymeric phosphorylcholine-camptothecin conjugates prepared by controlled free radical polymerization and click chemistry.
Chen X; McRae S; Parelkar S; Emrick T
Bioconjug Chem; 2009 Dec; 20(12):2331-41. PubMed ID: 19899739
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Anticancer Efficacy and Toxicity Studies of a Novel Polymer Conjugate N-Acetyl Glucosamine (NAG)-PEG-Doxorubicin for Targeted Cancer Therapy.
Pawar S; Mahajan K; Vavia P
AAPS PharmSciTech; 2017 Nov; 18(8):3021-3033. PubMed ID: 28497240
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers.
Liang Y; Li S; Wang X; Zhang Y; Sun Y; Wang Y; Wang X; He B; Dai W; Zhang H; Wang X; Zhang Q
J Control Release; 2018 Apr; 275():129-141. PubMed ID: 29408580
[TBL] [Abstract][Full Text] [Related]
15. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery.
Du C; Deng D; Shan L; Wan S; Cao J; Tian J; Achilefu S; Gu Y
Biomaterials; 2013 Apr; 34(12):3087-97. PubMed ID: 23374705
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted and stimulus-responsive polymeric prodrug nanoparticles to enhance the anticancer therapeutic efficacy of doxorubicin.
Kim N; Kwon S; Kwon G; Song N; Jo H; Kim C; Park S; Lee D
J Control Release; 2024 May; 369():351-362. PubMed ID: 38552963
[TBL] [Abstract][Full Text] [Related]
17. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
19. Amphiphilic polyelectrolyte/prodrug nanoparticles constructed by synergetic electrostatic and hydrophobic interactions with cooperative pH-sensitivity for controlled doxorubicin delivery.
Huang P; Wang W; Zhou J; Zhao F; Zhang Y; Liu J; Liu J; Dong A; Kong D; Zhang J
ACS Appl Mater Interfaces; 2015 Mar; 7(11):6340-50. PubMed ID: 25746122
[TBL] [Abstract][Full Text] [Related]
20. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
